Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.00T
Market cap1.00T
Price-Earnings ratio
37.50
Price-Earnings ratio37.50
Dividend yield
0.60%
Dividend yield0.60%
Average volume
2.97M
Average volume2.97M
High today
$1,069.11
High today$1,069.11
Low today
$1,047.07
Low today$1,047.07
Open price
$1,049.45
Open price$1,049.45
Volume
1.90M
Volume1.90M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

Eli Lilly(LLY) stock is priced at $1,064.48, giving the company a market capitalization of 1T. It carries a P/E multiple of 37.50 and pays a dividend yield of 59.8%.

On 2026-05-22, Eli Lilly(LLY) stock traded between a low of $1,047.07 and a high of $1,069.11. Shares are currently priced at $1,064.48, which is +1.7% above the low and -0.4% below the high.

The Eli Lilly(LLY)'s current trading volume is 1.9M, compared to an average daily volume of 2.97M.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,133.95 and a 52-week low of $623.78.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,133.95 and a 52-week low of $623.78.

LLY News

Benzinga 2h
Eli Lilly Highlights Positive Late-Stage Foundayo Data At Obesity Conference - Benzinga

...

Eli Lilly Highlights Positive Late-Stage Foundayo Data At Obesity Conference - Benzinga
TipRanks 2h
Eli Lilly Expands Heart Failure Pipeline With New Phase 1 Trial of LY3971297

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Start a conversation with TipRanks’ trusted, data-backed investment intelligen...

TipRanks 2h
Eli Lilly’s Remternetug Study Reaches Completion, Setting the Stage in Alzheimer’s Drug Race

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Start a conversation with TipRanks’ trusted, data-backed investment intelligen...

Analyst ratings

85%

of 33 ratings
Buy
84.8%
Hold
12.1%
Sell
3%

More LLY News

TipRanks 2h
Lilly’s Tirzepatide Ramadan Study Nears Data Phase, Eyeing a Key Diabetes Market Segment

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Start a conversation with TipRanks’ trusted, data-backed investment intelligen...

TipRanks 2h
Lilly and Rigel Advance RA Pipeline as Key LY3871801 Mid-Stage Trial Reaches Completion

Eli Lilly And Company (LLY), Rigel Pharmaceuticals (RIGL) announced an update on their ongoing clinical study. Start a conversation with TipRanks’ trusted, dat...

Simply Wall St 7h
Is It Too Late To Consider Eli Lilly After Its Recent Share Price Surge?

Wondering whether Eli Lilly's share price still reflects fair value, or if expectations have started to run ahead of the fundamentals? This article breaks down...

Is It Too Late To Consider Eli Lilly After Its Recent Share Price Surge?
Benzinga 1d
Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss

The study evaluated retatrutide, a triple hormone receptor agonist targeting GIP, GLP-1, and glucagon pathways, in adults with obesity or overweight and at leas...

Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss
TipRanks 1d
Eli Lilly’s Next-Generation Weight-Loss Drug Clears Big Hurdle

U.S. pharmaceutical giant Eli Lilly (LLY) says its next-generation weight-loss drug has cleared a late-stage clinical trial in patients who are obese. Start a...

Barron's 1d
Eli Lilly’s New GLP-1 Drug Looks Like a Weight-Loss Powerhouse in New Trial

Biotech and Pharma Eli Lilly’s New GLP-1 Drug Looks Like a Weight-Loss Powerhouse in New Trial In this article LLY NVO Eli Lilly shares have fallen around 5% so...

Eli Lilly’s New GLP-1 Drug Looks Like a Weight-Loss Powerhouse in New Trial
TipRanks 1d
Eli Lilly’s retatrutide readout strengthens long-term narrative, says Truist

Truist keeps the firm’s Buy rating and a $1,281 price target on Eli Lilly (LLY). The company’s retatrutide Phase 3 clinical trial data in obesity announced this...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.